Neoplasms

All Conditions

Carcinoma, Small Cell

Carcinoma

Neoplasms, Glandular and Epithelial

Neoplasms by Histologic Type

Patients receive Serplulimab IV over 30 minutes +/- 10 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients undergo radiation therapy QD on days 1-5 during weeks 1-3 only. Patients undergo PET/CT scan, CT, and MRI throughout the trial. Patients also undergo blood and tissue collection throughout the trial.

Patients receive Serplulimab IV over 30 minutes +/- 10 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients undergo PET/CT scan, CT, and MRI throughout the trial. Patients also undergo blood and tissue collection throughout the trial.

4.5mg/kg,IV over 30 minutes +/- 10 minutes on day 1. Cycles repeat every 21 days.

Serplulimab

Chest Radiation

Yun Fan, PHD

jing Qin

This phase II trial compares the effect of adding radiation therapy to the usual maintenance therapy with Serplulimab versus Serplulimab alone in patients who have already received Serplulimab plus chemotherapy for the treatment of extensive stage small cell lung cancer .

This phase II trial compares the effect of adding radiation therapy to the usual maintenance therapy with Serplulimab versus Serplulimab alone in patients who have already received Serplulimab plus chemotherapy for the treatment of extensive stage small cell lung cancer . Immunotherapy with monoclonal antibodies, such as Serplulimab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Giving radiation therapy in addition to Serplulimab may extend the time without extensive small cell lung cancer growing or spreading compared to Serplulimab alone.

Testing the Addition of Radiation Therapy to the Immune Therapy Treatment for ES-SCLC

A Randomized Controlled, Multicenter Phase II Study to Evaluate the Efficacy and Safety of Combination Therapy With Serplulimab and RT in Patients With ES-SCLC Who Have Not Progressed After Treat With Serplulimab Combined Chemotherapy

An adverse event was defined as any untoward medical occurrence in a participant

PFS rate after 1 year after randomization

defined as time from randomization to the date of first observed disease progression (investigator assessment according to RECIST 1.1) or death from any cause

defined as the time from initiation of study treatment to death from any cause

defined as the time from the first occurrence of a documented objective response to disease progression or death from any cause (whichever occurs first), as determined by the investigator according to RECIST v1.1.

defined as the proportion of participants who have a best overall response of CR or PR or stable disease (SD), as determined by the investigator according to RECIST v1.1.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Testing the Addition of Radiation Therapy to the Immune Therapy Treatment for ES-SCLC	NCT06350162	Extensive Stage...	Serplulimab Chest Radiation	18 Years - 75 Years	Zhejiang Cancer Hospital
Testing the Addition of Radiation Therapy to the Immune Therapy Treatment for ES-SCLC	NCT06350162	Extensive Stage...	Serplulimab Chest Radiation	18 Years - 75 Years	Zhejiang Cancer Hospital

Spots Global Cancer Trial Database for extensive stage lung small cell cancer